Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)

NCT02163577 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT02163577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02163577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 2, 2014
Completion date
October 30, 2018
Enrollment
52 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked hypophosphatemia